This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 2, 2012 08:30 am ET
Paul Friedman – President & Chief Executive Officer
Patricia Andrews – Executive Vice President & Chief Commercial Officer
Dave Hastings – Executive Vice President & Chief Financial Officer
Rich Levy – Executive Vice President & Chief Drug Development and Medical Officer
Pamela Murphy – Vice President, Investor Relations and Corporate Communications
Matt Roden – UBS
Brian Abrahams – Wells Fargo
Salveen Richter – Canaccord Genuity
Ian Somaiya – Piper Jaffray
Cory Kasimov – JP Morgan
Thomas Wei – Jefferies & Co.
Rachel McMinn – Bank of America
Tom Russo – Robert W. Baird
Lisa Bayko – JMP Securities
Eric Schmidt – Cowen & Company
Christina – Barclays Capital
David Friedman – Morgan Stanley
Boris Peaker – Oppenheimer
David Crump – Morningstar
Mani Mohindru – ThinkEquity
Greetings, ladies and gentlemen, and welcome to the Incyte Corporation’s Q2 2012 Earnings Call. A brief question-and-answer session will follow the formal presentation. (Operator instructions.) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ms. Pamela Murphy, Vice President Investor Relations and Communications. Thank you Ms. Murphy, you may now begin.
Good morning and welcome to Incyte’s Q2 2012 conference call. On the call today are Paul Friedman, Incyte’s President and Chief Executive Officer; Pat Andrews, Executive Vice President and Chief Commercial Officer; Dave Hastings, Executive Vice President and Chief Financial Officer; and Rich Levy, Executive Vice President and Chief Drug Development and Medical Officer. Pat is traveling outside of the country right now and is therefore not in the room with us. Paul will begin with a brief overview of the quarter, Pat will update you on the product launch of Jakafi, and Dave will describe the Q2 2012 financial results.